Physician profile
Kasandra J Risch
NPI 1306265699
$6,967.91
in general payments reported to CMS, 2019-2025
62 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,308 · 2022: $1,424 · 2023: $1,421 · 2024: $1,186 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,203 · Education: $33.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,203.17 |
| Education | $33.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $704.69 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $605.66 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Jazz Pharmaceuticals INC. | $467.13 | 2021-2025 | |
| Janssen Biotech, INC. | $442.70 | 2021-2025 | Tecvayli, Rybrevant, Erleada |
| Pfizer INC. | $413.53 | 2021-2025 | |
| Genentech USA, INC. | $377.99 | 2021-2025 | Polivy, Phesgo, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $359.49 | 2021-2025 | Calquence, Lynparza, Enhertu |
| Celgene Corporation | $317.02 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $272.26 | 2021-2025 | Iclusig, Ninlaro, Fruzaqla |
| Genzyme Corporation | $167.52 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $166.26 | 2022-2025 | Libtayo, Lynozyfic |
| Daiichi Sankyo INC. | $158.34 | 2021-2025 | Enhertu, Injectafer |
| Abbvie INC. | $145.36 | 2021-2025 | |
| Eisai INC. | $131.63 | 2021-2025 | |
| Incyte Corporation | $131.47 | 2021-2025 | Monjuvi, Jakafi |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $126.65 | 2021-2025 | Ojjaara, Blenrep |
| Epizyme, INC. | $104.88 | 2021 | |
| Aveo Pharmaceuticals, INC. | $102.97 | 2022-2025 | Fotivda |
| E.R. Squibb & Sons, L.L.C. | $89.35 | 2021-2025 | Opdivo |
| Springworks Therapeutics, INC. | $87.61 | 2024-2025 | Ogsiveo |
| Amgen INC. | $87.50 | 2021-2024 | Kyprolis, Blincyto |
| Lilly USA, LLC | $81.70 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Dendreon Pharmaceuticals LLC | $76.66 | 2024-2025 | Provenge |
| Beone Medicines USA, INC. | $76.62 | 2025 | Brukinsa, Tevimbra |
| Seagen INC. | $65.79 | 2021-2023 | Padcev |
| Array Biopharma INC | $65.42 | 2022-2024 | Mektovi, Braftovi, Lorbrena |
| Pharmacyclics LLC, An Abbvie Company | $64.46 | 2021-2022 | |
| Puma Biotechnology, INC. | $60.90 | 2021-2023 | |
| Genmab U.S., INC. | $58.52 | 2025 | Epkinly |
| Gilead Sciences, INC. | $58.01 | 2021-2022 | |
| Taiho Oncology, INC. | $57.39 | 2021-2024 | |
| Pharmaessentia USA Corporation | $55.00 | 2022-2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $53.08 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $43.24 | 2021-2022 | |
| Tersera Therapeutics LLC | $42.49 | 2022-2023 | Zoladex |
| Mirati Therapeutics, INC. | $39.75 | 2023-2024 | Krazati |
| Sumitomo Pharma America, INC. | $39.46 | 2023-2024 | Orgovyx |
| Morphosys, US INC. | $37.85 | 2021 | |
| Adc Therapeutics America, INC. | $35.55 | 2022 | |
| Acrotech Biopharma INC. | $34.13 | 2022-2023 | Beleodaq |
| Emd Serono, INC. | $33.31 | 2022 | |
| Astellas Pharma US INC | $32.70 | 2025 | Xospata, Padcev |
| Kite Pharma, INC. | $32.52 | 2022-2024 | Yescarta |
| Stemline Therapeutics INC. | $28.39 | 2023-2024 | Orserdu |
| Sanofi US Services INC. | $24.88 | 2025 | |
| Shorla Oncology INC. | $24.68 | 2025 | |
| Progenics Pharmaceuticals, INC. | $22.14 | 2023 | Pylarify |
| Coherus Oncology, INC. | $22.08 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.62 | 2023 | Onivyde, Somatuline Depot |
| Janssen Scientific Affairs, LLC | $20.81 | 2024 | Akeega, Pipeline, Erleada |
| Eagle Pharmaceuticals, INC. | $20.64 | 2022 | |
| Myovant Sciences INC. | $20.33 | 2021 | |
| Organon LLC | $19.61 | 2023 | Ontruzant |
| Spectrum Pharmaceuticals INC. | $18.98 | 2024 | Rolvedon |
| Blue Earth Diagnostics | $18.23 | 2021 | |
| Servier Pharmaceuticals LLC | $16.62 | 2023 | |
| Medtronic, INC. | $15.61 | 2025 | Osteocool Rf Ablation System |
| Lundbeck LLC | $15.01 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.52 | 2023 | |
| Kyowa Kirin, INC. | $13.94 | 2025 | |
| Beigene USA, INC. | $13.47 | 2022 | |
| Foundation Medicine, INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasandra Risch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.